-
Nature sub-magazine breakthrough! Fasting with vitamin C is effective for hard-to-treat cancers
Time of Update: 2020-06-17
, June 6, 2020 / BioValley /PRNewswire/ -- Scientists from the University of Southern California (USC) and the IFOM Cancer Institute in Milan have found that a diet that mimics fasting may be more e
-
Lancet sub-journal: The reasons behind this year's record-breaking drop in cancer diagnoses are worrying!
Time of Update: 2020-06-17
, June 7, 2020 /PRNewswire/ -- Cancer care has changed dramatically as a result of the COVID-19 pandemic: many patients do not see a gp or delay their treatment, but are later transferred to hospit
-
Selected Compilation: Car T-cell targeted therapy GBM with high efficiency specificity
Time of Update: 2020-06-17
There is still a lack of effective treatment for glioblastoma (GBM) In recent years, the expression chimeric antigen receptor (CAR) T cells obtained through the technological transformation of genetic
-
New medicine for myeloma! Sanofi CD38 Antibody Sarclisa Combination Therapy Phase III Clinically Significantly Prolonged ProgressIon Survival, Deep Remission!
Time of Update: 2020-06-17
, June 10, 2020 / BIOON/Sanofi has announced positive results from a clinical trial of CD38-targeted antibody drug Sarclisa (isatumab) for recurrent and/or refractable multiple myeloma (MM) PHASE I
-
PNAS: Nanoparticles stimulate the immune system and help it attack tumors
Time of Update: 2020-06-17
, June 10, 2020 /PRNewswire/ -- Biovalley BIOON /- Suppresses the immune system, so these types of treatments are not suitable for all patients MIT engineers have now come up with a way to improve
-
Three-pronged treatment for three-negative breast cancer (TNBC)! BMS and UbiVac partnered with cancer vaccine DPV-001/anti-OX40/anti-PD-1 triple therapy!
Time of Update: 2020-06-17
, June 10, 2020 /PRNewswire/ -- Cancer vaccine developer UbiVac and BMS have recently reached a clinical trial partnership to evaluate a pioneering cancer vaccine, DPV-001, developed using autophagy
-
BRAF inhibitor Braftovi approved by the European Medicines Agency for the treatment of colorectal cancer in conjunction with EGFR antibody Erbitux
Time of Update: 2020-06-16
The BRAF inhibitor Braftovi (encorafenib) and EGFR-targeted antibody Erbitux (cetuximab) were approved by the European Medicines Agency for use as a second-line treatment for patients previously unde
-
Lancet oncol: Phase III Trial: The Efficacy and Safety of Ripretinib Single Drug for the Treatment of Late Gastroenteric Tumors
Time of Update: 2020-06-16
Resistance to approved KIT primary cancer genes, receptor tyrosine kinase (KIT) and platelet-source growth factor receptor (PDGFRA) inhibitors is a clinical challenge for patients with advanced gastr
-
Blood: HLA-B pilot genotype predicts hlA mismatch with prognosis of bloodless donor HCT
Time of Update: 2020-06-16
Hematopoietic cell transplantation (HCT) from hlA mismatched non-blood-related donors can cure life-threatening blood diseases, but its success rate is limited by graft-resistant host disease (GVHD)
-
NEJM: Skin colon cancer metastasis in surgical scars - case report
Time of Update: 2020-06-16
The patient was a 59-year-old man with metastatic colon cancer who was admitted to the dermatology department for possible shingles He has a 10-week history of painless and itch-free skin lesions, wh
-
Blood: A new neuroamide analogue and mechanism that can effectively inhibit invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating invivating in
Time of Update: 2020-06-16
Primary oozed lymphoma (PEL) is an invasive malignant tumor with poor prognosis even in the case of active chemotherapy, usually accompanied by Kaposi sarcoma-associated herpes virus (Kaposi's sarcom
-
Summary of latest advances in non-small cell lung cancer, MET-positive targeted treatment
Time of Update: 2020-06-16
2020ASCO series small cell lung cancer, immuno-targeted treatment latest progress summary non-small cell lung cancer, targeted treatment latest progress summary non-small cell lung cancer, MET-positi
-
EHA 2020: Latest advances in Roche's CD20xCD3 dual-specific antibody glofitamab treatment for lymphoma
Time of Update: 2020-06-16
At the 25th annual meeting of the European Society of Hematology, Roche announced the latest data on its CD20xCD3 T-cell bispecific antibody glofitamab (formerly known as CD20-TCB) for patients with
-
Blood: Efficacy and safety of netoplasm for relapse of blood malignancies after alloHCT
Time of Update: 2020-06-16
CTLA-4 blocking enhances the anti-tumor effect of an allogeneic hematopoietic cell transplant (alloHCT) in recurrent malignant blood disease (HMs) The interaction of PD-1/PDL-1 can also lead to impai
-
Thyroid: Metabolic Syndrome and Risk of Thyroid Cancer
Time of Update: 2020-06-16
The relationship between metabolic syndrome and its components and the risk of thyroid cancer is not clear In a recent study published in the authoritative journal Thyroid, researchers conducted a la
-
Blood: HHEX and Mutant ASXL1 work together to promote myelin transformation
Time of Update: 2020-06-16
The Additional Sex Combs-like 1, ASXL1 encodes a chromatin binding protein, an epigenetic regulatory factor that mutates frequently in myelin tumors Recent analysis of mutant ASXL1 condition knock-in
-
Female, found gallbladder polyps 5 days, please diagnose!
Time of Update: 2020-06-16
"Department" hepatobiliary surgery patients, female, 37-year-old "main complaint" physical examination found that gallbladder polyps 5 days, not related treatment "current medical history" found gall
-
NEJM: Efficacy and Safety of Tepotinib in MET Exon 14 Jump Mutation in NSCLC
Time of Update: 2020-06-16
Globally, lung cancer is the most common type of cancer and the leading cause of cancer death, with 2 million cases diagnosed and 1.7 million deaths diagnosed each year MET signaling pathway changes,
-
Cell: Single Cell Map of Tumor stumor and immune ecosystem of human breast cancer
Time of Update: 2020-06-16
Breast cancer is a heterogeneous disease Tumor cells and associated healthy cells form ecosystems that determine disease progress and response to treatment To characterize the characteristics of the
-
Blood: Effect of human-derived Fc receptor non-binding anti-CD3 monoclonal antibodies in T-ALL
Time of Update: 2020-06-16
T-cell acute lymphoblastic leukemia (T-ALL) is an invasive malignant tumor that accounts for about 20% of ALL cases Intensive chemotherapy regimens have a cure rate of more than 85%, but less than 50
